<DOC>
	<DOCNO>NCT00282282</DOCNO>
	<brief_summary>The purpose study extend use Tacrolimus Sirolimus determine effective prevent graft versus host disease ( GVHD ) patient receive non-myeloablative peripheral blood stem cell transplantation .</brief_summary>
	<brief_title>Tacrolimus Sirolimus Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>- After screen procedure confirm patient eligible participate research study , admit hospital receive chemotherapy stem cell transplantation ( SCT ) . The duration hospitalization procedure approximately 8 day . - Patients receive fludarabine daily 30 minute intravenously 4 day busulfex daily 3 hour intravenously day 4 day . - Just prior transplant follow transplant patient receive sirolimus tacrolimus help prevent Graft versus Host Disease ( GvHD ) . Both medication take orally . - Patients also take medication help prevent possible infection ( e.g . acyclovir ) . Filgrastim , white blood cell growth factor , give daily injection skin , start day stem cell transplant patient blood count recover . - After stem cell infusion , patient examine blood test weekly 1 month . At 1-month visit , bone marrow biopsy and/or blood test perform determine percentage donor 's cell blood bone marrow . These test repeat 3-4 month transplant . - At 3-4 month transplant , patient also test reassess response disease transplant . This may involve bone marrow biopsy , blood test , and/or radiology study depend upon type cancer . - Follow-up continue remainder patient life .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients hematologic malignancy high risk complication conventional transplantation Availability relate donor identical 6 HLA locus Greater 18 year age Performance status 02 Life expectancy &gt; 100 day Pregnancy Evidence HIV infection Heart failure uncontrolled medication Total bilirubin &gt; 2.0mg/dl due hepatocellular dysfunction AST &gt; 90 Serum Creatinine &gt; 2.0 Cholesterol &gt; 300mg/dl adequately treat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>non-myeloablative peripheral blood stem cell</keyword>
	<keyword>PBSCT</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
</DOC>